# Spain Biosimilar Contract Manufacturing Market

> Spain Biosimilar Contract Manufacturing Market Research Report By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian) and By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 18.89%
- **2024:** $ 270.5 Million
- **2025:** $ 321.6 Million
- **2035:** $ 1,815 Million
- **Key Players:** Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US)

**Report ID:** MRFR/Pharma/50117-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/spain-biosimilar-contract-manufacturing-market-51875

---

## Market Summary

## **Spain Biosimilar Contract Manufacturing Market Overview**

As per MRFR analysis, the Spain Biosimilar Contract Manufacturing Market Size was estimated at 162.53 (USD Million) in 2023. The Spain Biosimilar Contract Manufacturing Market Industry is expected to grow from 193.25(USD Million) in 2024 to 1,616.7 (USD Million) by 2035. The Spain Biosimilar Contract Manufacturing Market CAGR (growth rate) is expected to be around 21.301% during the forecast period (2025 - 2035).

### **Key Spain Biosimilar Contract Manufacturing Market Trends Highlighted**

The Spain Biosimilar Contract Manufacturing Market is experiencing substantial growth, which is being driven by a variety of critical market factors. In Spain, the government is actively promoting the use of biosimilars to reduce drug spending and increase patient access to essential medicines, which is one of the most prominent drivers of the increasing demand for affordable healthcare solutions.

This is consistent with Spain's national health strategy, which underscores the significance of cost-effective therapies in maintaining public health. Local manufacturers are investing in advanced biomanufacturing technologies to produce biosimilars more efficiently, which is enabling them to appeal to a broader range of therapeutic areas, including oncology and autoimmune diseases. Consequently, opportunities within this market are continuing to expand.

The regulatory support for biosimilars in Spain has been reflected in notable trends in recent times. The Spanish Medicines Agency has created a favorable environment for the approval and use of biosimilars, which is enticing both domestic and international companies to increase their investments. Furthermore, the market is experiencing further growth as healthcare providers become increasingly confident in the safety and efficacy of biosimilars.

Another trend is the collaboration between biotech firms and contract manufacturers to optimize production processes, thereby ensuring that high-quality biosimilars comply with rigorous regulations. In general, Spain's biosimilar contract manufacturing landscape is undergoing rapid evolution; however, it continues to prioritize the improvement of patient access, the promotion of innovation, and the cultivation of competitive market dynamics that are advantageous to all parties.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

### **Spain Biosimilar Contract Manufacturing Market Drivers**

#### **Rising Demand for Cost-Effective Biopharmaceuticals**

The Spain Biosimilar Contract Manufacturing Market Industry is witnessing a substantial rise in demand for cost-effective biopharmaceuticals. With the annual cost of brand-name biologic therapies often exceeding 100,000 Euros per patient, there is a significant push toward biosimilars, which can be up to 30% cheaper.

According to a study by the Spanish Ministry of Health, the potential savings from biosimilars could reach over 1 billion Euros annually by 2025. Companies like Almirall and Bioiberica are investing in biosimilar manufacturing capabilities to capitalize on this trend, further driving growth in the market.

#### **Increasing Regulatory Support for Biosimilars**

The Spanish regulatory environment is increasingly supportive of biosimilars, with the European Medicines Agency (EMA) streamlining approval processes. This support is critical in reducing the time to market for new biosimilars. In Spain, regulatory frameworks have been updated to enhance the manufacturing and approval processes of biosimilars, facilitating a faster introduction into the market.

Established organizations such as Grifols have played a pivotal role in advocating for these regulatory changes, indicating a growing support system for the Spain Biosimilar Contract Manufacturing Market Industry.

#### **Significant Growth in Chronic Disease Prevalence**

Chronic diseases such as diabetes, arthritis, and cancer are on the rise in Spain, leading to an increased demand for biosimilar products. The Spanish National Health System reports that approximately 1 in 5 adults are now living with chronic conditions, which require ongoing treatment often fulfilled by biosimilars.

With the aging population projected to increase significantly, companies like Merck Espaa are focusing their efforts on biosimilar production to meet this demand. This health trend is expected to significantly contribute to the growth of the Spain Biosimilar Contract Manufacturing Market Industry.

#### **Advancements in Biotechnology and Manufacturing Processes**

Recent advancements in biotechnology and manufacturing processes are driving the Spain Biosimilar Contract Manufacturing Market forward. New technologies such as single-use bioreactors and continuous manufacturing processes are enhancing production efficiency and scalability.

According to the Spanish biotechnology sector report, over 60% of biotechnology companies are investing in innovative manufacturing technologies. Companies like Reig Jofre are actively investing in these cutting-edge technologies, which not only streamline operations but also improve the overall quality of biosimilars, thus promoting market growth.

### **Spain Biosimilar Contract Manufacturing Market Segment Insights**

#### **Biosimilar Contract Manufacturing Market Product Insights**

The Spain Biosimilar Contract Manufacturing Market is witnessing notable growth dynamics within the Product segment, showcasing promising innovations and diverse applications. This segment can be delineated into Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins, each serving pivotal roles in the landscape of biopharmaceutical manufacturing.

Recombinant Non-glycosylated Proteins have garnered attention due to their vital function in therapeutic applications, particularly in areas such as hormone replacement, hematology, and immune response modulation.

Their production technology is often viewed as a significant advantage, facilitating the manufacture of highly pure and potent therapeutic substances in a cost-effective manner, which aligns well with the increasing demand for biologics in Spain’s healthcare sector.

On the other hand, Recombinant Glycosylated Proteins are essential for drug efficacy and are instrumental in a variety of therapeutic areas, including oncology and autoimmune diseases. These proteins possess complex glycosylation patterns that are crucial for their biological activity, stability, and therapeutic efficacy, making them indispensable in modern medicine.

As Spain advances its biopharmaceutical industry, the emphasis on high-quality biosimilars produced through contract manufacturing arrangements is expected to enhance access to treatments, reduce healthcare costs, and bolster patient outcomes. The Spain Biosimilar Contract Manufacturing Market beckons growth, driven by an increasing patient population and the growing prevalence of chronic diseases.

Key drivers transforming this market include technological advancements in protein engineering, optimized production processes, and a supportive regulatory landscape. Moreover, the collaborative efforts between pharmaceutical companies and contract manufacturers are fostering a more flexible and efficient production environment, promising timely access to biosimilar products while addressing the unique requirements of the Spanish healthcare framework.

Despite these opportunities, challenges such as stringent regulatory requirements and high initial setup costs may hinder market expansion. Nevertheless, opportunities abound for companies that excel in scalability and innovation, particularly in the development of novel therapeutic proteins to cater to unmet medical needs. The Spain Biosimilar Contract Manufacturing Market continues to evolve, reflecting broader trends in biopharmacy and the growing importance of biosimilars as key components in the treatment arsenal.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

#### **Biosimilar Contract Manufacturing Market Production Technology Insights**

The Spain Biosimilar Contract Manufacturing Market is witnessing significant growth within the Production Technology segment. This segment is primarily divided into Mammalian and Non-Mammalian production methods, which play critical roles in the manufacturing of biosimilars.

Mammalian cell lines are often preferred for the production of complex biologics due to their ability to perform post-translational modifications.

This makes them crucial for developing highly effective biosimilars that closely resemble their reference products.

On the other hand, Non-Mammalian systems, including microbial fermentation processes, offer cost-effective alternatives for producing simpler biologics. The decision between these two production technologies often depends on the specific biosimilar being developed and its intended therapeutic use.

As the demand for biosimilars continues to expand in Spain, especially in the treatment of chronic diseases, various firms are investing in advanced manufacturing technologies to optimize efficiency and compliance with regulatory standards. The growing focus on biopharmaceutical innovation, combined with supportive government initiatives aimed at enhancing the life sciences sector, contributes positively to the dynamics of the Production Technology segment in the Spanish market.

#### **Biosimilar Contract Manufacturing Market Application Insights**

The Spain Biosimilar Contract Manufacturing Market is characterized by various applications that cater to critical therapeutic areas. The oncology segment is particularly significant due to the increasing prevalence of cancer, motivating healthcare providers to seek cost-effective treatment alternatives.

Blood disorders also hold a crucial position in the market, with biosimilars offering competitive options for patients requiring these essential therapies. Growth Hormonal Deficiency remains a vital area, as effective solutions are needed for patients with specific hormonal needs, driving the market forward.

Chronic and autoimmune disorders, including rheumatoid arthritis, are gaining attention, reflecting changing demographics and the growing incidence of these complex conditions in Spain. In this evolving landscape, the continuous development of biosimilars contributes to the expansion of treatment options available for patients. As a result, the Spain Biosimilar Contract Manufacturing Market segmentation plays a pivotal role in enhancing accessibility and affordability of essential medications while addressing diverse healthcare needs across the region. With supportive policies promoting biosimilars, there are numerous opportunities for manufacturers to collaborate and innovate further in this space.

### **Spain Biosimilar Contract Manufacturing Market Key Players and Competitive Insights**

The Spain Biosimilar Contract Manufacturing Market is characterized by a rapidly evolving landscape where various companies are vying for dominance in a growing sector. Biosimilars, which are complex biologic medications highly similar to already approved reference products, have gained traction due to their potential to offer cost-effective treatment options.

The competitive dynamics within this market are shaped by numerous factors, including regulatory frameworks, technological advancements, and the strategic maneuvers adopted by market players. Companies operating in this space are increasingly investing in enhancing their manufacturing capabilities and optimizing supply chains to better serve the needs of patients and healthcare providers alike. As the demand for biosimilars continues to rise in Spain, competition will likely intensify, fostering innovation and pushing companies to establish strong partnerships to secure their market positions.

Biocon has established a noteworthy presence in the Spain Biosimilar Contract Manufacturing Market, leveraging its extensive experience and expertise in biologics manufacturing. The company's strength lies in its highly advanced production facilities that adhere to stringent international quality standards, enabling Biocon to ensure consistent product quality and reliability.

Additionally, Biocon has successfully built a reputation for its commitment to research and development, allowing for the continuous improvement of its biosimilar offerings. In Spain, the company has formed strategic collaborations with local stakeholders, enhancing its operational footprint and enabling it to respond to the needs of the market more effectively. The combination of an innovative approach, a strong manufacturing foundation, and collaborations positions Biocon favorably in the competitive landscape.

Sandoz, a prominent player in the Spain Biosimilar Contract Manufacturing Market, offers an extensive portfolio of biosimilar products that cater to various therapeutic areas, contributing significantly to its strong market presence. The company's strengths lie in its advanced manufacturing technologies and robust quality management systems, which allow for the development and production of high-quality biosimilars at scale.

Furthermore, Sandoz has pursued a series of strategic mergers and acquisitions to bolster its capabilities and expand its product offerings within the Spanish market. These initiatives have enabled Sandoz to strengthen its competitive edge by enhancing its research and development capabilities and broadening its distribution network. By focusing on providing affordable access to biologic medicines, Sandoz not only supports the healthcare ecosystem in Spain but also solidifies its role as a key player in the biosimilars market landscape.

#### **Key Companies in the Spain Biosimilar Contract Manufacturing Market Include**

### **Spain Biosimilar Contract Manufacturing Market Industry Developments**

In recent months, the Spain Biosimilar Contract Manufacturing Market has witnessed significant developments. Biocon announced the successful launch of its critical biosimilar product in Europe, contributing to its growing portfolio in the Spanish market as of August 2023. Sandoz continues to expand its capabilities by investing in new manufacturing facilities, enhancing its competitive edge within Spain.

Meanwhile, Merck KGaA has made strides in developing innovative biosimilars, particularly in oncology, reflecting the increasing demand for affordable treatment options in the region. Additionally, a noteworthy acquisition recently occurred with Fresenius Kabi acquiring a local manufacturing facility to bolster its production capacity in Spain in July 2023.

As the market value of biosimilars in Spain is projected to grow significantly, companies like Mylan and Stada Arzneimittel are also intensifying efforts to increase their market presence. The Spanish government's support for biotechnology through favorable regulations is fostering an environment ripe for market expansion, indicating a robust future for biosimilars in the healthcare sector. Major happenings include the rise of partnerships among key players in the last two years, focusing on enhancing Research and Development capabilities to meet market demand efficiently.

### **Spain Biosimilar Contract Manufacturing Market Segmentation Insights**

#### **Biosimilar Contract Manufacturing Market Product Outlook**

#### **Biosimilar Contract Manufacturing Market Production Technology Outlook**

#### **Biosimilar Contract Manufacturing Market Application Outlook**

## Market Drivers

### Increasing Healthcare Expenditure

The rising healthcare expenditure in Spain is a pivotal driver for the biosimilar contract-manufacturing market. As the Spanish government allocates more funds towards healthcare, the demand for affordable treatment options intensifies. In 2025, healthcare spending is projected to reach approximately €200 billion, reflecting a growth of around 5% from previous years. This increase in budget allows for the integration of biosimilars into treatment protocols, thereby enhancing patient access to essential medications. The biosimilar contract-manufacturing market stands to benefit significantly as pharmaceutical companies seek to leverage cost-effective production methods to meet this growing demand. Consequently, the market is likely to witness a surge in partnerships between biosimilar developers and contract manufacturers, aiming to optimize production efficiency and reduce costs.

### Aging Population and Chronic Diseases

Spain's demographic shift towards an aging population is a crucial factor influencing the biosimilar contract-manufacturing market. With an increasing number of individuals aged 65 and above, the prevalence of chronic diseases such as diabetes and arthritis is on the rise. By 2025, it is estimated that over 20% of the Spanish population will be over 65, leading to a heightened demand for biologic therapies. This demographic trend compels healthcare providers to explore biosimilars as a viable alternative to expensive biologics, thereby driving the need for contract manufacturing services. The biosimilar contract-manufacturing market is expected to expand as pharmaceutical companies aim to develop and produce biosimilars that cater to this growing patient demographic, ensuring that effective treatments are accessible and affordable.

### Rising Focus on Personalized Medicine

The growing emphasis on personalized medicine in Spain is emerging as a notable driver for the biosimilar contract-manufacturing market. As healthcare shifts towards tailored treatment approaches, the demand for biologics and their biosimilars is expected to rise. Personalized medicine aims to optimize therapeutic efficacy by considering individual patient characteristics, which may lead to increased utilization of biosimilars as alternatives to traditional biologics. In 2025, the market for personalized medicine in Spain is projected to grow by approximately 10%, indicating a shift in treatment paradigms. This trend encourages contract manufacturers to adapt their capabilities to meet the specific needs of biosimilar developers, thereby enhancing their service offerings and fostering innovation within the biosimilar contract-manufacturing market.

### Government Initiatives for Biosimilar Adoption

The Spanish government has implemented various initiatives to promote the adoption of biosimilars, which serves as a significant driver for the biosimilar contract-manufacturing market. Policies aimed at encouraging the use of biosimilars include financial incentives for healthcare providers and educational programs to raise awareness among patients and physicians. In 2025, the government is expected to allocate an additional €50 million towards these initiatives, further stimulating market growth. By fostering an environment conducive to biosimilar utilization, the government is likely to enhance competition among manufacturers, leading to lower prices and increased availability of biosimilars. This proactive approach not only benefits patients but also creates opportunities for contract manufacturers to engage with biosimilar developers, thereby expanding their market presence.

### Competitive Landscape and Market Entry Strategies

The competitive landscape within the biosimilar contract-manufacturing market is evolving, driven by the entry of new players and strategic collaborations. As established pharmaceutical companies seek to expand their portfolios, they are increasingly partnering with contract manufacturers to leverage their expertise in biosimilar production. In 2025, the number of contract manufacturing organizations (CMOs) specializing in biosimilars is expected to increase by 15%, reflecting a growing recognition of the market's potential. This influx of new entrants may lead to intensified competition, prompting existing players to innovate and enhance their service offerings. Consequently, the biosimilar contract-manufacturing market is likely to experience dynamic shifts as companies adopt various market entry strategies to secure their positions and capitalize on emerging opportunities.

## Future Outlook

The [Biosimilar Contract Manufacturing Market](https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903) in Spain is poised for growth at an 18.89% CAGR from 2025 to 2035, driven by increasing demand for cost-effective biologics and regulatory support.

**New opportunities:**

- Expansion of manufacturing capabilities for complex biosimilars
- Strategic partnerships with biotech firms for co-development
- Investment in advanced bioprocessing technologies to enhance efficiency

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Product: Recombinant Glycosylated Proteins (Largest) vs. Recombinant Non-glycosylated Proteins (Fastest-Growing)

In the Spain biosimilar contract-manufacturing market, the recombinant glycosylated proteins segment holds the largest share, reflecting the growing demand for these complex biologics. This type of protein is primarily used in therapies for various diseases, enhancing its market position as healthcare providers increasingly prefer glycosylated options for their efficacy and compatibility. Conversely, recombinant non-glycosylated proteins are emerging rapidly as they cater to specific therapeutic needs, particularly in oncology, where their simplified structure allows for faster production times and reduced costs.

The growth trends in this segment are driven by advancements in bioprocessing technologies and an increased focus on personalized medicine. The regulatory landscape is also evolving, facilitating quicker approvals for biosimilar products. With the rise in chronic diseases and the need for cost-effective therapeutic solutions, the recombinant non-glycosylated proteins are witnessing significant investments, thus establishing themselves as a fast-growing segment in the Spain biosimilar contract-manufacturing market.

Recombinant Glycosylated Proteins (Dominant) vs. Recombinant Non-glycosylated Proteins (Emerging)

Recombinant glycosylated proteins serve as the dominant segment in the Spain biosimilar contract-manufacturing market, favored for their structural complexity and proven effectiveness in treatment protocols. Their ability to mimic natural proteins in human biology ensures high therapeutic value, which has become essential in the management of various health conditions. In contrast, recombinant non-glycosylated proteins are emerging as an alternative due to their simpler molecular structures, allowing manufacturers to streamline production processes. This makes them particularly attractive for developing cost-effective solutions in the competitive landscape, especially in oncology and other specialty areas. As both segments evolve, they cater to distinct yet overlapping needs within the market.

### By Production Technology: Mammalian (Largest) vs. Non-Mammalian (Fastest-Growing)

In the Spain biosimilar contract-manufacturing market, the distribution of production technology reveals that mammalian systems hold the largest share, catering to the majority of biopharmaceutical needs due to their ability to produce complex proteins. On the other hand, non-mammalian technologies are gaining traction, capturing a significant niche, particularly in rapid production cycles and consistency.

Growth trends indicate a shift towards non-mammalian platforms, driven by advancements in genetic engineering and increasing demand for cost-effective production methods. Non-mammalian technologies, while still emerging, offer innovative solutions for companies looking to expedite their manufacturing processes, making them an attractive option in the competitive landscape of biosimilars. The market is witnessing a dynamic shift, with both segments contributing uniquely to the evolving biosimilar ecosystem.

Technology: Mammalian (Dominant) vs. Non-Mammalian (Emerging)

Mammalian production technology remains the dominant force in the biosimilar contract-manufacturing market, known for its superior ability to produce biologics that require post-translational modifications. This method leverages the intricate cellular machinery of mammalian cells to ensure biological activity and efficacy, making it a preferred choice for many biopharmaceutical manufacturers. Conversely, non-mammalian technologies, including yeast and bacterial systems, are emerging as viable alternatives, offering advantages such as shorter production times and lower operational costs. These emerging technologies appeal to manufacturers seeking to enhance flexibility and responsiveness to market demands, positioning them for rapid growth as the industry continues to evolve toward more efficient and scalable production methods.

### By Application: Oncology (Largest) vs. Chronic & Autoimmune Disorders (Fastest-Growing)

In the Spain biosimilar contract-manufacturing market, the application segment is prominently led by Oncology, which holds the largest market share due to the increasing prevalence of cancer and the growing acceptance of biosimilars among healthcare providers. Blood Disorders and Growth Hormonal Deficiency also contribute significantly, but at a smaller scale. Chronic & Autoimmune Disorders are showing an upward trend, indicating a rising demand in this area, driven by expanding patient populations and awareness regarding treatment options.

Growth trends in this segment are influenced by various factors, including advancements in biosimilar development and increasing healthcare expenditure. The rising incidence of chronic diseases along with favorable regulatory environments boosts the adoption of biosimilars in these therapeutic areas. Notably, the Chronic & Autoimmune Disorders segment is emerging as a significant player, reflecting changing treatment paradigms and a shift towards personalized medicine, catering to patient-specific needs.

Oncology (Dominant) vs. Chronic & Autoimmune Disorders (Emerging)

Oncology, as the dominant segment in the Spain biosimilar contract-manufacturing market, is characterized by an extensive range of biosimilar products designed to treat various types of cancer. Its dominance stems from the urgent need for cost-effective treatments in a high-burden disease area, which has led to increased investments in research and development. Conversely, Chronic & Autoimmune Disorders represent an emerging opportunity, with a growing array of biosimilars targeting diseases such as rheumatoid arthritis and multiple sclerosis. The shift towards biosimilars in this segment is propelled by the need for affordable alternatives to expensive biologics, improved patient access to therapies, and a supportive regulatory landscape that incentivizes biosimilar innovation.

## Competitive Benchmarking

The biosimilar contract-manufacturing market in Spain is characterized by a dynamic competitive landscape, driven by increasing demand for cost-effective biologics and the growing acceptance of biosimilars among healthcare providers. Key players such as Samsung Biologics (KR), Lonza Group (CH), and Boehringer Ingelheim (DE) are strategically positioned to leverage their extensive manufacturing capabilities and technological expertise. Samsung Biologics (KR) focuses on expanding its global footprint through strategic partnerships and investments in advanced manufacturing technologies, while Lonza Group (CH) emphasizes innovation in bioprocessing to enhance production efficiency. Boehringer Ingelheim (DE) is actively pursuing collaborations to strengthen its biosimilar portfolio, indicating a trend towards cooperative strategies that enhance competitive positioning.The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is particularly relevant in the context of increasing regulatory scrutiny and the need for rapid market entry. The collective influence of these major players shapes a competitive environment where agility and responsiveness to market demands are paramount.

In September  Fujifilm Diosynth Biotechnologies (JP) announced the expansion of its manufacturing facility in Spain, aimed at increasing production capacity for biosimilars. This strategic move is likely to enhance its ability to meet the rising demand for biosimilars in Europe, positioning the company as a key player in the region. The expansion reflects a broader trend of companies investing in local manufacturing capabilities to ensure supply chain resilience and compliance with regional regulations.

In October  Catalent (US) entered into a partnership with a leading European biopharmaceutical company to co-develop a new biosimilar product. This collaboration underscores Catalent's commitment to innovation and its strategic focus on enhancing its service offerings in the biosimilar space. By aligning with established biopharmaceutical firms, Catalent is likely to strengthen its market position and expand its portfolio, which may lead to increased competitiveness in the evolving landscape.

In November  Wuxi Biologics (CN) launched a new digital platform aimed at streamlining the biosimilar development process. This initiative is indicative of the growing trend towards digitalization within the industry, as companies seek to leverage technology to enhance operational efficiency and reduce time-to-market. The integration of digital solutions may provide Wuxi Biologics (CN) with a competitive edge, allowing for more agile responses to client needs and market changes.

As of November  current competitive trends in the biosimilar contract-manufacturing market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in manufacturing processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, supply chain reliability, and innovative product offerings, reflecting the industry's response to changing market dynamics.

## Recent News & Developments

In recent months, the Spain Biosimilar Contract Manufacturing Market has witnessed significant developments. Biocon announced the successful launch of its critical biosimilar product in Europe, contributing to its growing portfolio in the Spanish market as of August 2023. Sandoz continues to expand its capabilities by investing in new manufacturing facilities, enhancing its competitive edge within Spain.

Meanwhile, Merck KGaA has made strides in developing innovative biosimilars, particularly in oncology, reflecting the increasing demand for affordable treatment options in the region. Additionally, a noteworthy acquisition recently occurred with Fresenius Kabi acquiring a local manufacturing facility to bolster its production capacity in Spain in July 2023.

As the market value of biosimilars in Spain is projected to grow significantly, companies like Mylan and Stada Arzneimittel are also intensifying efforts to increase their market presence. The Spanish government's support for biotechnology through favorable regulations is fostering an environment ripe for market expansion, indicating a robust future for biosimilars in the healthcare sector. Major happenings include the rise of partnerships among key players in the last two years, focusing on enhancing Research and Development capabilities to meet market demand efficiently.

## Report Scope

| MARKET SIZE 2024 | 270.5(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 321.6(USD Million) |
| MARKET SIZE 2035 | 1815.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.89% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Catalent (US), Wuxi Biologics (CN), Rentschler Biopharma (DE), KBI Biopharma (US), Amgen (US) |
| Segments Covered | Product, Production Technology, Application |
| Key Market Opportunities | Growing demand for cost-effective biosimilars drives expansion in biosimilar contract-manufacturing market. |
| Key Market Dynamics | Rising demand for cost-effective biosimilars drives competitive contract-manufacturing partnerships in Spain's pharmaceutical sector. |
| Countries Covered | Spain |

## Frequently Asked Questions

**Q: What was the market valuation of the Spain biosimilar contract-manufacturing market in 2024?**
A: The market valuation was $270.5 Million in 2024.

**Q: What is the projected market valuation for the Spain biosimilar contract-manufacturing market by 2035?**
A: The projected valuation for 2035 is $1815.0 Million.

**Q: What is the expected CAGR for the Spain biosimilar contract-manufacturing market during the forecast period 2025 - 2035?**
A: The expected CAGR is 18.89% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the Spain biosimilar contract-manufacturing market?**
A: Key players include Samsung Biologics, Lonza Group, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, Catalent, Wuxi Biologics, Rentschler Biopharma, KBI Biopharma, and Amgen.

**Q: What were the valuations for recombinant non-glycosylated proteins in 2024?**
A: The valuation for recombinant non-glycosylated proteins was $108.0 Million in 2024.

**Q: What is the projected valuation for recombinant glycosylated proteins by 2035?**
A: The projected valuation for recombinant glycosylated proteins is $1167.0 Million by 2035.

**Q: What were the production technology valuations for mammalian and non-mammalian segments in 2024?**
A: In 2024, mammalian production technology was valued at $150.0 Million, while non-mammalian was valued at $120.5 Million.

**Q: What is the projected valuation for chronic & autoimmune disorders in the Spain biosimilar contract-manufacturing market by 2035?**
A: The projected valuation for chronic & autoimmune disorders is $350.0 Million by 2035.

**Q: What were the valuations for oncology and blood disorders applications in 2024?**
A: In 2024, oncology applications were valued at $40.0 Million, and blood disorders were valued at $30.0 Million.

**Q: What is the expected growth trend for the Spain biosimilar contract-manufacturing market in the coming years?**
A: The market is expected to grow significantly, with a projected valuation increase to $1815.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/spain-biosimilar-contract-manufacturing-market-51875*